Press Releases Chugai Pharmaceutical Co., Ltd. OTC Markets

Equities

CHGCY

US1712691039

Market Closed - OTC Markets Other stock markets 01:29:59 29/06/2024 am IST			5-day change	1st Jan Change
17.77 ^USD	-1.77%		+10.65%	-5.73%

24/06	Japan's Nikkei ends choppy session on stronger note	RE
24/06	Japan's Nikkei squeezes out gains in choppy session	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Chugai Pharmaceutical : Announcement of a Director Resignation	12:35pm	PU
Chugai Pharmaceutical : All pages, single page [PDF	24/06	PU
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO in the UK and Ireland	13/06	AQ
Chugai Pharmaceutical - Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System, Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company	12/06	AQ
Chugai Pharmaceutical - Maruho Announces Launch of Mitchga Subcutaneous Injection 30mg Vials in Japan	12/06	AQ
Chugai Pharmaceutical : Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company	11/06	PU
Chugai Pharmaceutical : Personnel Changes	29/05	PU
Chugai Pharmaceutical : Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Provide Information on Detection of Copy Number Alterations of Cancer-Related Genes and bTMB Score	27/05	PU
Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure, Improving access to the clinical trial for patients far from the institution	09/05	AQ
Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan	26/04	PU
Chugai Announces 2024 1st Quarter Results	25/04	AQ
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)	24/04	PU
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024	24/04	PU
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	15/04	AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	10/04	AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	28/03	AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	28/03	PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	27/03	AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	27/03	AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	27/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Chugai Pharmaceutical Co., Ltd. OTC Markets

Equities

CHGCY

US1712691039

Press Releases

Filters